Robert S. Wallis

Biography

Robert Wallis received his B.A. (1978) from Antioch College , and M.D. (1982) from Case Western Reserve University School of Medicine. He completed a Residency in Internal Medicine and postdoctoral Fellowship in Infectious Diseases at the University Hospitals of Cleveland , and then became a member of the faculty of the Department of Medicine at CWRU in 1987. In 2000, he moved his laboratory to the University of Medicine and Dentistry of New Jersey, where he directed clinical and research activities of the Division of Infectious Diseases of the New Jersey Medical School . His academic career focused on laboratory-based studies of mycobacterial pathogenesis and immunity, and international clinical trials of tuberculosis diagnosis, treatment, and monitoring, and of the co-pathogenesis of HIV and tuberculosis. In 2004, Dr. Wallis became Medical Director at PPD, Inc., a global contract research organization that provides discovery, development and post-approval services for industry, academia, and government. In 2008, he took his present position with Pfizer, where he is Clinical Group Lead for Anti-Infectives and Clinical Lead for Pfizer's TB oxazolidinone program. Dr. Wallis maintains adjunct faculty appointments at both his former universities, where he continues to be actively involved in laboratory and translational research. Robert Wallis received his B.A. (1978) from Antioch College , and M.D. (1982) from Case Western Reserve University School of Medicine. He completed a Residency in Internal Medicine and postdoctoral Fellowship in Infectious Diseases at the University Hospitals of Cleveland , and then became a member of the faculty of the Department of Medicine at CWRU in 1987. In 2000, he moved his laboratory to the University of Medicine and Dentistry of New Jersey, where he directed clinical and research activities of the Division of Infectious Diseases of the New Jersey Medical School . His academic career focused on laboratory-based studies of mycobacterial pathogenesis and immunity, and international clinical trials of tuberculosis diagnosis, treatment, and monitoring, and of the co-pathogenesis of HIV and tuberculosis. In 2004, Dr. Wallis became Medical Director at PPD, Inc., a global contract research organization that provides discovery, development and post-approval services for industry, academia, and government. In 2008, he took his present position with Pfizer, where he is Clinical Group Lead for Anti-Infectives and Clinical Lead for Pfizer's TB oxazolidinone program. Dr. Wallis maintains adjunct faculty appointments at both his former universities, where he continues to be actively involved in laboratory and translational research.

Research Interest

Internal Medicine